Lyell Immunopharma’s recently acquired CAR-T doesn’t appear to impress Wall Street. The company said Tuesday that its dual-targeting CD19/CD20 CAR-T called LYL314 induced 22 responses in a cohort of 25 patients …
- Enhancing chromatographic protein purification with light June 17, 2025
- UCB commits major US biologics manufacturing investment June 16, 2025
- MHRA Class 2 medicine recalls – May/June 2025 June 13, 2025
- Lancet study illustrates drug delivery “milestone” June 12, 2025
- FDA grants expanded approval for hepatitis drug June 11, 2025
- Construction begins on new WuXi microbial manufacturing site June 10, 2025
- Biosimilar Manufacturers to Expand Offerings in Europe and Japan June 16, 2025
- Third Circuit Holds That Granting Discovery Under Section 1782 Is Not a “Final” Judgment June 13, 2025
- Sandoz Launches PYZCHIVA® (Ustekinumab) Autoinjector in Europe June 4, 2025
- Samsung Bioepis Secures Marketing Approval in Korea for its Biosimilar to Amgen’s Bone Cancer Drug Xgeva June 3, 2025
- EMA Issues Positive CHMP Opinions for Fresenius Denosumab Biosimilars June 2, 2025
- The Top Pharmacy Benefit Managers of 2024: Market Share and Key Industry Developments (rerun) June 17, 2025
- The Top 15 U.S. Pharmacies of 2024: Market Shares and Revenues at the Biggest Chains, PBMs, and Specialty Pharmacies (rerun) June 16, 2025
- Starting with the End in Mind: How Pharma Can Build a Smarter Path to Commercialization June 13, 2025
- The 340B Contract Pharmacy Market in 2025: Big Chains and PBMs Tighten Their Grip June 10, 2025
- Moving Beyond Mitigation: Cracking the Maximizer Code to Protect Patient Affordability June 6, 2025
- Pharmacist Salaries and Employment in 2024: Retail Employment Collapse Offset by Hospital Boom June 3, 2025
- Three Ways GoodRx Is Helping Pharmacies Increase Profitability and Drive Innovation May 30, 2025